Just Like Family Home Care, a trusted Canadian company, is proud to announce the launch of its services in Newmarket, Aurora, ...

Fat Loss and Body Recomposition: SARMs aid in fat burning by increasing metabolic rate and preserving lean muscle during fat ...

At AscellaHealth, we recognize that a one-size-fits-all approach doesn’t work when distributing therapies for individuals with complex, chronic and rare diseases,” says Bill Oldham, Chairman and ...

Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, today announced the appointment of ...

This information is synthesized by PanOmiQ™ of BioAro Inc, World’s Fastest AI powered MultiOmics Platform, integrated with wearable data (HRV, sleep, workload), and delivered through easy-to-use ...

Multipronged approach to overcome the challenge of anti-drug antibodies to serve as the foundation of new subsidiary, AdaMunix ...

The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data. Most treatment-emergent adverse ...

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of July 2025, which is payable on ...

Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension BASKING RIDGE, N.J, July 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc ...

BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT™, plus immune check point inhibitor (CPI) versus physician’s choice in a dvanced metastatic b reast ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of ...

- Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - ...